OHP-079 Tumor Necrosis Factor Blockers in Rheumatology; Conventional Versus Off-Label Drug Dosage

Review Study: Intravenous Thrombolysis, Time Window, Dosage, and Off-Label

Despite the development of Intravenous thrombolysis with tissue Plasminogen Activator (IVtPA) guidelines in each affiliated stroke center, protocol violations may be observed in each hospital with IVtPA facilities. An extensive search of scientific electronic databases including PubMed, OVID, Index Medicus, Index Copernicus, Google, ISI, and Scopus was performed with keywords of Thrombolysis, O...

Induction of systemic lupus erythematosus with tumor necrosis factor blockers.

Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity.

BACKGROUND Tumor necrosis factor (TNF) plays a pathogenic role in rheumatoid arthritis but is essential for antimycobacterial host defenses. The risk of reactivation of latent Mycobacterium tuberculosis infection is greater with the TNF monoclonal antibody infliximab than with the soluble TNF receptor etanercept. The basis of this difference is not known. METHODS The effects that the monoclon...

Tumor necrosis factor blockers influence macrophage responses to Mycobacterium tuberculosis.

Tumor necrosis factor (TNF)-alpha is a proinflammatory cytokine that mediates inflammation in response to various pathogens, including Mycobacterium tuberculosis, but is also a key factor in the pathogenesis of rheumatoid arthritis and other autoimmune diseases. Three TNF-alpha-suppressing drugs have been approved to treat selected autoimmune diseases; 2 are monoclonal antibodies against TNF-al...

Making tumor necrosis factor blockers safer: a prescriber's consumptive challenge.